PREVENTING URINARY TRACT INFECTIONS
VIOBAC announces collaboration with former regional purchasing manager, Lars Dahl Allerup
Lars Dahl Allerup joins VIOBAC as new co-owner, board-member and strategic advisor. Through his great expertise he will contribute to strategi development, business maturation, go-to-market strategy, value-based sales and more.
Catheter-associated urinary tract infections (CAUTIs) have been reported as the most common hospital acquired infection in the world being responsible for up to 40% of all hospital infections, with more than 1 million cases per year in the US alone.
Approximately 25 % of hospitalized patients will undergo urinary catheterization, and nearly 30 % of these will develop CAUTI.
The risk of getting a urinary tract infection (UTI) among catherized patients is estimated to be up to 10 % per day, while 100 % are expected to have a UTI after 3 weeks of catherization.
The bacteria are capable of adhering to catheter surfaces in bacterial communities known as biofilm, having greater resistance to the natural immune system of the host as well as being almost resistant to antimicrobials and virtually impossible to eradicate without removing the catheter.
VIOBAC has invented a solution to the problem.
By using a small, unique, patented click-on medical device, we aim to prevent catheter associated infections with simple germicidal UV-technology.
This could potentially be the first prophylactic approach with clinical significant effect.
The solution is developed to prevent bacteria from getting into the patients urinary tract system - and will thereby prevent unnecessary urinary tract infections from happening when using a catheter.
The visions of VIOBAC are driven by two medical doctors with true patient and hospital experience, in collaboration with more than 20 life science professionals including expertise within the fields of microbiology, design- and electromechanics, IP, product purchase and regulatory affairs.
The right IP rights and essential in the world of medical technology.
Our solution has national patent granted and international (PCT) patent pending.
The efficacy of our solution has now been proven in professional laboratory settings. We continue to gather firm evidence.
We have partnered up with a major developer of medical equipment in order to optimize our product and regulatory demands.
VIOBAC has been voted the best university startup in the world within the health category with incorporation of the UN's 17 Sustainable Development Goals, 2019.
University Startup World Cup
VIOBAC has been chosen as one of the 10 selected participants for NHTT 2019 hosted by Venture Cup
Nordic Health Tech Talents
VIOBAC was named as one of the winners of the 2019 EIT Health Scandinavia Headstart Award.
EIT Health Headstart
PARTNERSHIPS // COLLABORATIONS
500 Terry Francois Street San Francisco, CA 94158
ALTERNATIVELY YOU CAN FILL IN THE FOLLOWING CONTACT FORM:
TO SPEAK WITH AN AGENT,
PLEASE CALL OR EMAIL US:
GET IN CONTACT
Lyshøjgårdsvej 47, 4. th
FEEL FREE TO MESSAGE US!
For any contact please use the contact form or the following information
Tel: +45 2611 3220